Market Cap 1.65B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 4,987,664
Avg Vol 6,986,420
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 48%
Beta 1.14
Analysts Strong Sell
Price Target $10.50

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
PaulHall398
PaulHall398 Jul. 31 at 8:52 PM
$ABCL Interesting point around blinded trials. You can sometimes get early signals even under confidential diligence, but the data is still limited by the study design. Good signs are great. Just need to remember what they can and can’t prove.
0 · Reply
8008track
8008track Jul. 31 at 8:13 PM
$ABCL all in all it was a decent close to the day and week. I added to my position pretty much every day this week. I am now looking forward to the earnings call next week. Should be fun. Have a great weekend!
0 · Reply
TheBiotechInvestor_
TheBiotechInvestor_ Jul. 31 at 7:14 PM
0 · Reply
tradersunion353
tradersunion353 Jul. 31 at 6:45 PM
$ABCL 8.40 to 5 dollars in 2 weeks and 635 phase leaked data . management is least bothered abbout updating investors meanwhile clowns who are married to ABCL are cheerleading with adding and loading comments - clowns
0 · Reply
tradersunion353
tradersunion353 Jul. 31 at 5:45 PM
$ABCL i’m still not getting what these clowns are celebrating for? POS stock
0 · Reply
PulsarProtocol
PulsarProtocol Jul. 31 at 3:38 PM
$ABCL In this market, feeling comfortable in small-cap biotech is rare. The only way I get confidence is by focusing on the data, cash position, pipeline quality, and execution.Volatility is part of the game, but strong fundamentals create the foundation to hold through it.
0 · Reply
Rastafari
Rastafari Jul. 31 at 2:56 PM
$ABCL 3 new jobs listed on July 28th : 2 for cell screening and 1 for lead biology. You only hire if you see revenue!
0 · Reply
Stockingtrade
Stockingtrade Jul. 31 at 2:28 PM
$ABCL With the rest of the market tanking the last while, ABCL seems like a safe harbor for gains. Love to see it!
0 · Reply
Rastafari
Rastafari Jul. 31 at 2:11 PM
$ABCL One idea I keep coming back to is whether ABCL’s AI‑driven discovery engine—combined with its growing internal pipeline—can evolve into the kind of repeatable value‑creation machine that VelocImmune became for Regeneron. Not just a source of service revenue, but a platform that consistently produces its own high‑value medicines.Regeneron built an entire empire on that model. The stock is trading around $733 today, a testament to what a true discovery engine can become. Hold on to your stock and don’t let them scare you into selling!
1 · Reply
8008track
8008track Jul. 31 at 1:59 PM
$ABCL bought more
0 · Reply
Latest News on ABCL
AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 24 days ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ


AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 25 days ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 25 days ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 2 months ago

AbCellera appoints Victor Sandor to board of directors


AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 2 months ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 3 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 4 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 5 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 5 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 11 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024


AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024


AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


PaulHall398
PaulHall398 Jul. 31 at 8:52 PM
$ABCL Interesting point around blinded trials. You can sometimes get early signals even under confidential diligence, but the data is still limited by the study design. Good signs are great. Just need to remember what they can and can’t prove.
0 · Reply
8008track
8008track Jul. 31 at 8:13 PM
$ABCL all in all it was a decent close to the day and week. I added to my position pretty much every day this week. I am now looking forward to the earnings call next week. Should be fun. Have a great weekend!
0 · Reply
TheBiotechInvestor_
TheBiotechInvestor_ Jul. 31 at 7:14 PM
0 · Reply
tradersunion353
tradersunion353 Jul. 31 at 6:45 PM
$ABCL 8.40 to 5 dollars in 2 weeks and 635 phase leaked data . management is least bothered abbout updating investors meanwhile clowns who are married to ABCL are cheerleading with adding and loading comments - clowns
0 · Reply
tradersunion353
tradersunion353 Jul. 31 at 5:45 PM
$ABCL i’m still not getting what these clowns are celebrating for? POS stock
0 · Reply
PulsarProtocol
PulsarProtocol Jul. 31 at 3:38 PM
$ABCL In this market, feeling comfortable in small-cap biotech is rare. The only way I get confidence is by focusing on the data, cash position, pipeline quality, and execution.Volatility is part of the game, but strong fundamentals create the foundation to hold through it.
0 · Reply
Rastafari
Rastafari Jul. 31 at 2:56 PM
$ABCL 3 new jobs listed on July 28th : 2 for cell screening and 1 for lead biology. You only hire if you see revenue!
0 · Reply
Stockingtrade
Stockingtrade Jul. 31 at 2:28 PM
$ABCL With the rest of the market tanking the last while, ABCL seems like a safe harbor for gains. Love to see it!
0 · Reply
Rastafari
Rastafari Jul. 31 at 2:11 PM
$ABCL One idea I keep coming back to is whether ABCL’s AI‑driven discovery engine—combined with its growing internal pipeline—can evolve into the kind of repeatable value‑creation machine that VelocImmune became for Regeneron. Not just a source of service revenue, but a platform that consistently produces its own high‑value medicines.Regeneron built an entire empire on that model. The stock is trading around $733 today, a testament to what a true discovery engine can become. Hold on to your stock and don’t let them scare you into selling!
1 · Reply
8008track
8008track Jul. 31 at 1:59 PM
$ABCL bought more
0 · Reply
Stockingtrade
Stockingtrade Jul. 31 at 1:52 PM
$ABCL Wheeeeee!!!
0 · Reply
Olivia_Strickland
Olivia_Strickland Jul. 31 at 11:20 AM
$ABCL running hot premarket, +9.8% at 5.92 off yesterday's 5.69 close. no read on it yet, chart's telling the story right now. pull it up and tell me what you're seeing on the tape live premarket tape: https://tapeboard.com/go/st/research/ABCL?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=abcl-pm-up-tape&utm_term=research
0 · Reply
SPMudson
SPMudson Jul. 31 at 11:10 AM
0 · Reply
Planetpaprika
Planetpaprika Jul. 31 at 11:05 AM
$ABCL A report released yesterday : D. Chatterjee / JonesTrading maintained a Buy rating on AbCellera Biologics. Price target of $13.00. Chatterjee is a 5-star analyst with an average return of 43.0% and a 65.9% success rate. That´s not bad. She covers the healthcare sector... AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $10.20. Cantor Fitzgerald also maintained in July a Buy rating with a $11.00 price target.
0 · Reply
Olivia_Strickland
Olivia_Strickland Jul. 31 at 9:18 AM
$ABCL gapping 9% premarket but volume's paper thin at 72K. these verticals can fade hard into the open if the bid doesn't thicken up. anyone seeing what's pushing this or am I early on the scanner live premarket tape: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=abcl-pm-up-tape&utm_term=scanner&s=ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 31 at 9:12 AM
$ABCL Launch Pad ready 🚀
0 · Reply
SuperGreenToday
SuperGreenToday Jul. 31 at 7:10 AM
$ABCL Share Price: $5.70 Contract Selected: Jan 15, 2027 $5 Calls Buy Zone: $1.21 – $1.49 Target Zone: $2.30 – $2.81 Potential Upside: 80% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Stockingtrade
Stockingtrade Jul. 31 at 3:39 AM
$ABCL How high we going tomorrow?!?
2 · Reply
Plan2TradeTrade2Plan
Plan2TradeTrade2Plan Jul. 31 at 2:12 AM
$ABCL if this goes to $70 again, I’m moving to Vancouver! 🚀🚀
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 31 at 12:22 AM
$ABCL The market is valuing $ABCL based on what it used to be. Unpredictable research revenue. COVID-era biotech. Years of heavy spending. No approved internal medicines. But look at what is happening now: ABCL635 has entered Phase 2. ABCL575 is in Phase 1. Jazz paid $56M upfront. Vertex followed with another $28M . The company has approximately $655M of available liquidity. The risks haven’t disappeared. ABCL635 could fail, partnerships could stall and the cash burn remains significant. But AbCellera is finally approaching the period when years of investment begin producing clinical data and commercial validation. I am excited for the future.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 11:12 PM
$ABCL When I wrote this, the Jazz partnership was my latest evidence. Now Vertex has followed. Two major pharmaceutical companies have committed $84M in combined upfront payments to access AbCellera’s T-cell engager platform while funding the partnered R&D and leaving $ABCL with milestone and royalty upside. One partnership can be dismissed as a deal. Two major partners arriving back-to-back begins to look like repeatable platform validation. The $20B thesis will not be proven by one partnership or one drug. It depends on AbCellera repeatedly creating valuable medicines for partners and for itself. Jazz was evidence. Vertex is more evidence. ABCL635 Phase 2 is the next major test. I’ll keep documenting the thesis, the numbers and the risks as the evidence develops. Follow if you’re interested in where this story goes.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 10:41 PM
$ABCL Vertex bigger than most people think. They don’t just partner with anyone.
0 · Reply